Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02742883 : A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG)
PhasePhase 2
AgesMin: 3 Months Max: 70 Years
Eligibility
Inclusion Criteria:

Five cohorts of patients with diffuse, intrinsic pontine glioma will be studied:

1. Patients age 3 months to < 3 years;

2. Patients age 3-21 years with progressive disease (PD) following radiation therapy
(RT) ± chemotherapy and/or other therapies;

3. Patients age 3-21 years with newly diagnosed DIPG who (or whose parents / guardians)
have refused RT;

4. Patients age > 21 years with PD following RT ± chemotherapy and/or other therapies;
and

5. Patients age > 21 years with newly diagnosed DIPG who have refused RT.

Exclusion Criteria include:

1. Disseminated disease, multicentric tumors, or leptomeningeal disease;

2. Uncontrolled intercurrent illness;

3. A history of New York Heart Association Class II congestive heart failure or above;

4. Pregnancy.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02742883      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740